

To NASDAQ OMX Copenhagen A/S

Translation

Company release No 3/2009

Hørsholm
February 6, 2009

Shareholder announcement

Page 1/1

Pursuant to section 28(a) of the Danish Public Companies Act and section 29 of the Danish Securities Trading Act, ALK has received notification from ATP (the Danish Labour Market Supplementary Pension) that ATP and ATP Invest, Hillerød, Denmark, have reduced their ownership in ALK-Abelló A/S.

ATP and ATP Invest now own 8.81% of the company share capital equivalent to 891,850 shares and 4.84% of the votes.

ALK-Abelló A/S

Jens Bager
President and CEO

For further information please contact:

Per Plotnikof, Head of Investor Relations, tel. +45 4574 7527

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. Our mission is to improve quality of life for allergic people by developing pharmaceutical products that target the actual cause of allergy. ALK is the world leader in allergy vaccination (immunotherapy) – a unique treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. Allergy vaccination is traditionally administered as subcutaneous injections or sublingual droplets. Our aim is to extend the use of allergy vaccination by introducing convenient, tablet-based vaccines, thereby offering many more patients a causal allergy treatment. Following this strategy, the world's first tablet-based vaccine against grass pollen allergy, GRAZAX[®], was launched in Europe in 2007. ALK has entered into a strategic partnership regarding the tablet programme with Schering-Plough for North America. ALK has approximately 1,500 employees with subsidiaries, production facilities and distributors worldwide. The company is headquartered in Hørsholm, Denmark and listed on NASDAQ OMX Copenhagen A/S. 'ALK' is an abbreviation of 'Allergological Laboratory Copenhagen (København)'. Further information is available at www.alk-abello.com and www.GRAZAX.com.